GGrantIndex
← Leaderboards

Sergei P Atamas

University Of Maryland Baltimore

$2,647,768
Attributed
$2,647,768
Total exposure
6
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $383.8K · FY200518
$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$2,647,768 · 4
VA$0 · 2

By mechanism

R01$2,002,893 · 2
R21$422,125 · 1
R03$222,750 · 1
I01$0 · 2

Top collaborators

No co-investigators on record.

Most similar at University Of Maryland Baltimore

Same institution · by research overlap

Others in their field

Top investigators on “Collagen

Research focus

CollagenProductionCytokineInflammationFutureIn VivoMediatingLungFibrosisPlayCellsInterleukinsGene DeliveryFibroblastsBaseInflammatoryProteinsPathway InteractionsAsthmaCell Surface ReceptorsAttenuatedMolecularInvestigationAffect

Grant awards (20)

The Central Role of IL-33 in Immune-Mediated Scarring$0
I01 · FY2018 · VA · contact PI
The Mechanisms of Profibrotic Sensitization by IL33$345,375
R01 · FY2017 · HL · contact PI
The Central Role of IL-33 in Immune-Mediated Scarring$0
I01 · FY2017 · VA · contact PI
The Mechanisms of Profibrotic Sensitization by IL33$345,375
R01 · FY2016 · HL · contact PI
The Central Role of IL-33 in Immune-Mediated Scarring$0
I01 · FY2016 · VA · contact PI
The Mechanisms of Profibrotic Sensitization by IL33$383,750
R01 · FY2015 · HL · contact PI
The Central Role of IL-33 in Immune-Mediated Scarring$0
I01 · FY2015 · VA · contact PI
Unique immune regulation by alternatively spliced interleukin-4$0
I01 · FY2014 · VA · contact PI
Unique immune regulation by alternatively spliced interleukin-4$0
I01 · FY2013 · VA · contact PI
A Novel Model of, and Pre-clinical Therapy for, Scleroderma Lung Disease$191,875
R21 · FY2012 · HL · contact PI
Unique immune regulation by alternatively spliced interleukin-4$0
I01 · FY2012 · VA · contact PI
A Novel Model of, and Pre-clinical Therapy for, Scleroderma Lung Disease$230,250
R21 · FY2011 · HL · contact PI
Unique immune regulation by alternatively spliced interleukin-4$0
I01 · FY2011 · VA · contact PI
Molecular Mechanism of PARC-Mediated Lung Fibrosis$209,074
R01 · FY2007 · HL · contact PI
Molecular Mechanism of PARC-Mediated Lung Fibrosis$215,319
R01 · FY2006 · HL · contact PI
Molecular Mechanism of PARC-Mediated Lung Fibrosis$252,000
R01 · FY2005 · HL
Molecular Mechanism of PARC-Mediated Lung Fibrosis$252,000
R01 · FY2004 · HL
CD40 Regulation of IL-4 and IFN-g Effects on Fibroblasts$74,250
R03 · FY2003 · AR
CD40 Regulation of IL-4 and IFN-g Effects on Fibroblasts$74,250
R03 · FY2002 · AR
CD40 Regulation of IL-4 and IFN-g Effects on Fibroblasts$74,250
R03 · FY2001 · AR